Gemcitabine Plus Liposomal Doxorubicin for Relapsed Refractory T-Cell Lymphomas

Hematological Oncology - United Kingdom
doi 10.1002/hon.2439_166
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Phase I Study of Romidepsin and Liposomal Doxorubicin in Relapsed or Refractory T-Cell Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Pegylated Liposomal Doxorubicin in the Treatment of Primary Cutaneous T-Cell Lymphomas

Haematologica
Hematology
2007English

Cd19-Directed Car T Cell Therapy (Ctl019) for Relapsed/Refractory Diffuse Large B-Cell and Follicular Lymphomas: Four Year Outcomes

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Treatment of Relapsed and Refractory T-Cell Lymphomas: First Pavlov State Medical University of Saint-Petersburg Experience

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Final Overall Survival Results of a Randomized Trial Comparing Bortezomib Plus Pegylated Liposomal Doxorubicin With Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma

Cancer
Cancer ResearchOncology
2016English

A Phase I/Ii Trial of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma

Clinical Cancer Research
Cancer ResearchOncology
2019English

Randomized Phase II Study of the PDGFRα Antibody Olaratumab Plus Liposomal Doxorubicin Versus Liposomal Doxorubicin Alone in Patients With Platinum-Refractory or Platinum-Resistant Advanced Ovarian Cancer

BMC Cancer
Cancer ResearchOncologyGenetics
2018English

Single Agent Gemcitabine in Refractory or Relapsed Small-Cell Lung Cancer. Phase II Study

Research in Oncology
2007English

Clinical Outcomes From Venetoclax Based Therapy in Patients With Relapsed/Refractory B-Cell Lymphomas

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy